CYBIN INC
HELPNASDAQTrading Snapshot
- Day Range
- $10.04 – $10.22
- 52-Week Range
- —
- Volume
- $3.19B
- Avg Volume
- $4.13B
- Shares Outstanding
- 69.9M
- Next Earnings
- Sep 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $144M
- Last Q Revenue
- $37M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own HELP
- ✓High-growth profile — revenue up +57.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 77% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About CYBIN INC
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading include NAMI, BNED, YXT, TENX, MSC, B, VRSK, XFOR, HELP, and SLDB.
Helus Pharma Appoints Michael Halstead CEO, Effective Immediately
Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists
Wells Fargo Initiates Coverage On Helus Pharma with Overweight Rating, Announces Price Target of $16
Wells Fargo analyst Benjamin Burnett initiates coverage on Helus Pharma (NASDAQ:HELP) with a Overweight rating and announces Price Target of $16.
Crude Oil Surges 2%; 3M Shares Gain After Q2 Results
US stocks trade higher as Dow Jones gains over 350 points. Tech shares rise by 2% while consumer staples fall. 3M Co. sees 9% jump after strong earnings.
Hasbro, Utz Brands, Park Aerospace And Other Big Stocks Moving Higher On Tuesday
US stocks rise, Nasdaq gains 1%. Hasbro Inc (HAS) up 8.6% on strong Q2 results and raised sales guidance. Other gainers: UTZ, AEHR, PKE, FWRD, HELP, SECZ, DOCN, TRAX, PVLA, COIN.
Helus Pharma Completes Enrollment In Its APPROACH Phase 3 Study Of HLP003 In Patients Living With Major Depressive Disorder; Topline Data Readout On Track For Q4 2026
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM ProgramParticipant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability dataHLP003 previously